Acadian Asset Management LLC Takes $3.73 Million Position in Humana Inc. $HUM

Key Points

• Acadian Asset Management LLC has acquired a new position in Humana Inc., purchasing 14,084 shares valued at approximately $3.73 million in the first quarter.
• Humana Inc. reported earnings of $6.27 EPS for the last quarter, missing expectations, but its revenue increased by 9.6% year-over-year to $32.39 billion.
• The company has declared a quarterly dividend of $0.885 per share, with a dividend yield of 1.3%, to be paid on October 31st.

Acadian Asset Management LLC bought a new stake in shares of Humana Inc. (NYSE:HUM - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 14,084 shares of the insurance provider's stock, valued at approximately $3,726,000.

Other large investors have also recently bought and sold shares of the company. Cary Street Partners Investment Advisory LLC raised its position in Humana by 63.9% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock valued at $31,000 after buying an additional 46 shares during the period. Riverview Trust Co acquired a new position in Humana in the 1st quarter worth about $34,000. Garde Capital Inc. acquired a new position in shares of Humana during the 1st quarter valued at about $36,000. Zions Bancorporation National Association UT acquired a new position in shares of Humana during the 1st quarter valued at about $37,000. Finally, Whipplewood Advisors LLC increased its holdings in shares of Humana by 639.1% during the 1st quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock valued at $45,000 after acquiring an additional 147 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Price Performance

Humana stock opened at $276.36 on Monday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. The company has a market capitalization of $33.24 billion, a PE ratio of 21.21, a price-to-earnings-growth ratio of 1.62 and a beta of 0.44. Humana Inc. has a one year low of $206.87 and a one year high of $325.75. The business has a 50 day simple moving average of $265.34 and a 200 day simple moving average of $257.17.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). The company had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.Humana's quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter last year, the business earned $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. On average, sell-side analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.3%. The ex-dividend date is Friday, September 26th. Humana's dividend payout ratio (DPR) is 27.17%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on HUM shares. Piper Sandler lowered their price objective on Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a report on Thursday, July 31st. Sanford C. Bernstein increased their target price on Humana from $269.00 to $341.00 and gave the company an "outperform" rating in a research note on Friday, September 5th. Wall Street Zen downgraded Humana from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Morgan Stanley decreased their target price on Humana from $290.00 to $277.00 and set an "equal weight" rating for the company in a research note on Thursday, July 31st. Finally, Bank of America increased their target price on Humana from $285.00 to $312.00 and gave the company a "neutral" rating in a research note on Tuesday, September 2nd. Seven equities research analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $289.24.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.